318 related articles for article (PubMed ID: 16440400)
1. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
2. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
[TBL] [Abstract][Full Text] [Related]
3. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
Timerbaev AR; Foteeva LS; Rudnev AV; Abramski JK; Połeć-Pawlak K; Hartinger CG; Jarosz M; Keppler BK
Electrophoresis; 2007 Jul; 28(13):2235-40. PubMed ID: 17557359
[TBL] [Abstract][Full Text] [Related]
4. Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.
Groessl M; Hartinger CG; Polec-Pawlak K; Jarosz M; Keppler BK
Electrophoresis; 2008 May; 29(10):2224-32. PubMed ID: 18512673
[TBL] [Abstract][Full Text] [Related]
5. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
[TBL] [Abstract][Full Text] [Related]
6. CE in anticancer metallodrug research--an update.
Hartinger CG; Keppler BK
Electrophoresis; 2007 Oct; 28(19):3436-46. PubMed ID: 17847132
[TBL] [Abstract][Full Text] [Related]
7. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.
Groessl M; Hartinger CG; Dyson PJ; Keppler BK
J Inorg Biochem; 2008; 102(5-6):1060-5. PubMed ID: 18222004
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
9. Metallomics for drug development: an integrated CE-ICP-MS and ICP-MS approach reveals the speciation changes for an investigational ruthenium(III) drug bound to holo-transferrin in simulated cancer cytosol.
Aleksenko SS; Matczuk M; Lu X; Foteeva LS; Pawlak K; Timerbaev AR; Jarosz M
Metallomics; 2013 Aug; 5(8):955-63. PubMed ID: 23799586
[TBL] [Abstract][Full Text] [Related]
10. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
Hartinger CG; Zorbas-Seifried S; Jakupec MA; Kynast B; Zorbas H; Keppler BK
J Inorg Biochem; 2006 May; 100(5-6):891-904. PubMed ID: 16603249
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
Heffeter P; Pongratz M; Steiner E; Chiba P; Jakupec MA; Elbling L; Marian B; Körner W; Sevelda F; Micksche M; Keppler BK; Berger W
J Pharmacol Exp Ther; 2005 Jan; 312(1):281-9. PubMed ID: 15331656
[TBL] [Abstract][Full Text] [Related]
13. A versatile approach for assaying in vitro metallodrug metabolism using CE hyphenated with ICP-MS.
Abramski JK; Foteeva LS; Pawlak K; Timerbaev AR; Jarosz M
Analyst; 2009 Oct; 134(10):1999-2002. PubMed ID: 19768206
[TBL] [Abstract][Full Text] [Related]
14. Metallomics for drug development: serum protein binding and analysis of an anticancer tris(8-quinolinolato)gallium(III) drug using inductively coupled plasma mass spectrometry.
Ossipov K; Foteeva LS; Seregina IF; Perevalov SA; Timerbaev AR; Bolshov MA
Anal Chim Acta; 2013 Jun; 785():22-6. PubMed ID: 23764439
[TBL] [Abstract][Full Text] [Related]
15. Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method.
Rudnev AV; Aleksenko SS; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK
J Sep Sci; 2005 Feb; 28(2):121-7. PubMed ID: 15754818
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
[TBL] [Abstract][Full Text] [Related]
17. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins.
Rudnev AV; Foteeva LS; Kowol C; Berger R; Jakupec MA; Arion VB; Timerbaev AR; Keppler BK
J Inorg Biochem; 2006 Nov; 100(11):1819-26. PubMed ID: 16938349
[TBL] [Abstract][Full Text] [Related]
19. Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis.
Aleksenko SS; Hartinger CG; Semenova O; Meelich K; Timerbaev AR; Keppler BK
J Chromatogr A; 2007 Jul; 1155(2):218-21. PubMed ID: 17240384
[TBL] [Abstract][Full Text] [Related]
20. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
Bijelic A; Theiner S; Keppler BK; Rompel A
J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
